Compare
NewcelX Ltd. vs Decoy Therapeutics Inc. vs Lantern Pharma Inc. vs Turn Therapeutics Inc.
| Latest fiscal year | NewcelX Ltd. NCEL | Decoy Therapeutics Inc. DCOY | Lantern Pharma Inc. LTRN | Turn Therapeutics Inc. TTRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$8.30M | -$12.52M | -$17.12M | -$3.19M |
| EPS (Diluted) | $2.16 | -$129.10 | -$1.57 | -$0.12 |
| Operating cash flow | -$2.77M | -$4.83M | -$15.68M | -$2.56M |
| Free cash flow | -$2.77M | -$5.40M | -$15.68M | n/a |
| Cash & equivalents | $2.20M | $10.71M | $4.42M | $4.03M |
| Total assets | $11.45M | $11.06M | $11.04M | $12.16M |
| Total liabilities | $4.20M | $5.17M | $4.50M | $7.48M |
| Shareholders' equity | $7.25M | $5.89M | $6.53M | $4.69M |
| Return on year-end equity | -114.5% | -212.6% | -262.0% | -68.2% |
| Shares outstanding | 4.80M | n/a | 11.25M | 29.45M |
Revenue, most recent five fiscal years
| Fiscal year | NewcelX Ltd. | Decoy Therapeutics Inc. | Lantern Pharma Inc. | Turn Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2022-12-31 | n/a | n/a |
| 1 year earlier | n/a | $1.84M Ended 2021-12-31 | n/a | n/a |
| 2 years earlier | n/a | $5.23M Ended 2020-12-31 | n/a | n/a |
| 3 years earlier | n/a | $3.47M Ended 2019-12-31 | n/a | n/a |
| 4 years earlier | n/a | $1.95M Ended 2018-12-31 | n/a | n/a |